Tissue inhibitor of metalloproteinase (TIMP)-3 is a natural inhibitor of a range of enzymes that degrade connective tissue and are involved in the pathogenesis of conditions such as arthritis and cancer. We describe here the engineering of TIMP-3 using a novel drug-delivery system known as the 'LAP technology'. This 
TIMP-3 using a novel drug-delivery system known as the 'LAP technology'. This TIMP-3 has the widest inhibitory activity amongst the TIMPs, inhibiting not just the MMPs but many members of the related adamalysins (ADAM) 2 and adamalysins with thrombospondin motifs (ADAMTSs). 3 Unfortunately, development of synthetic inhibitors of
MMPs has not performed well in clinical trials causing severe toxicity and a musculoskeletal syndrome involving joint pain, oedema, and reduced mobility. 4 The broad nature of these inhibitors is deemed responsible for these side effects, so any future development of this approach will require more selective inhibitors. 5, 6 We have been working for a number of years on a novel drug delivery system, known as the latency-associated peptide ('LAP') fusion protein technology. This strategy is based on creating recombinant therapeutic proteins, such as anti-inflammatory cytokines, in an inactive (latent) form, so that they can be administered systemically without causing side effects. 7 This system is based on the (see Figure 1A ). These molecules are also engineered with cleavage sites specific for proteases found at sites of inflammation. The LAP technology has a number of advantages: the therapy is given systemically and delivery is targeted to the site of disease; there are no effects on normal immune responses; and much greater doses of the therapeutic agent can be administered to achieve high local concentrations The aim of this study is to express TIMP-3 as a LAP-fusion protein with an MMP cleavage site and assess the latency of the expressed protein and subsequent biological activity upon MMP cleavage.
| ME TH ODS
Detailed materials and methods are provided in Data S1. LAP-TIMP-3 fusion proteins were cloned in pcDNA6 and expressed in HEK 293T cells. Enzyme activity assays for ADAMTS-4, ADAM17
and MMP as well as a bovine cartilage explant assay were used to assess the biological activity of LAP-TIMP-3 before and after incubation with MMP. Synovial fluids and sera from patients undergoing joint replacement surgery for OA were collected after obtaining informed written consent and tested for their ability to cleave LAP-TIMP-3.
| RESULTS

| Expression of LAP-TIMP-3 and cleavage with
MMP-1
Mature human TIMP-3 was expressed as a LAP-fusion protein with a truncated cleavage site that was efficiently cleaved by recombinant MMP-1 ( Figure 1B) . Cleavage resulted in a residual leucine at the N terminus of the TIMP-3 released from the LAP. As previous studies had indicated that any additional amino acids substantially altered the biological activity of TIMP-3, 12 we also expressed L-TIMP to determine the effect of this extra N-terminal amino acid on biological activity. This version of TIMP-3 was produced in much lower quantities in HEK 293T cells than LAP-TIMP-3 ( Figure 1C ), but when purified, retained inhibitory activity for ADAMTS-4 ( Figure 1D ) and ADAM17
( Figure 1E ), but not for MMP ( Figure 1F ). Figure 2D , Figure S1 ).
F I G U R E 2 Cleavage of LAP-TIMP-3 releases biologically active TIMP-3. A, Western blot of various fractions from affinity purification LAP-TIMP-3 via the N-terminal
Sera from OA patients did not cleave the LAP-TIMP-3 and cleavage was also inhibited by addition of EDTA to synovial fluids or to MMP ( Figure 2E ).
| DISCUSSION
We report here a novel method of producing recombinant TIMP-3 in a mammalian cell culture system that can also be used to deliver the protein to sites of disease. The presence of the LAP drastically increased the quantity of TIMP-3 that could be purified. This increased yield of LAP-TIMP-3 compared with that reported by other groups may also be a consequence of using the His-tag on the N terminus of the fusion protein for purification. Previous studies relied on the C-terminal FLAG tag on TIMP-3 which is subject to substantial processing and decreased overall yields of purified material. 13 However, there was also much greater quantities of TIMP-3 accumulating in the medium when expressed as a LAP-fusion protein and we hypothesize that this could be a consequence of LAP preventing interactions with cellular receptors and subsequent endocytosis; indeed it is this function that makes it possible to produce latent molecules. 8 Consistent with this hypothesis is our observation that LAP-fusions of molecules whose ligands are soluble are not latent ( Figure S2 ).
As expected, TIMP-3 was a more specific inhibitor when produced as a LAP-fusion protein because of the residual leucine residue on the N terminus after cleavage with MMP. This is consistent with previous work on N-terminal mutants of TIMP-3 where the addition of an Nterminal alanine residue was sufficient to completely abrogate the inhibitory activity for MMPs, but retained the ability to inhibit aggrecanases. 12 This actually makes the prospect of LAP-TIMP-3 as a therapeutic more appealing. Clinical trials with inhibitors of MMPs have generally been disappointing because of adverse side effects which are attributed to the broad spectrum of the inhibitors tested. Greater specific activity could circumvent these problems previously encountered with the broad-spectrum MMP inhibitors 6 and could be used alongside existing therapies to improve clinical outcome.
An important finding of this study is that MMP cleavage of LAP-TIMP-3 was essential for biological activity of the molecule as shown in both the in vitro enzyme assays and in the cartilage degradation assay. The LAP technology is designed to allow systemic administration of the latent protein into the circulation and subsequent cleavage and accumulation at sites of inflammation via cleavage by MMPs. Therefore, our finding that there is sufficient MMP activity in OA synovial fluid to cleave LAP-TIMP-3, but not in OA patient serum, is important.
These data widen the therapeutic possibilities of LAP-TIMP-3, particularly as ADAM17 which contributes to pro-inflammatory TNF activity 14 was also inhibited by TIMP-3 when released from the LAP.
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